title: Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
abstract: OBJECTIVE
  To assess the effects of low-dose oral and transdermal estrogen therapy on the lipid profile and lipoprotein(a) [Lp(a)] levels in healthy, postmenopausal women and to study the additional influence of gestodene administration.
  
  
  METHODS
  In a multicenter, randomized, double-blind, placebo-controlled study, 152 healthy, hysterectomized, postmenopausal women received daily either placebo (n = 49), 50 microg transdermal 17beta-estradiol (tE2, n = 33), 1 mg oral 17beta-estradiol (oE2, n = 37), or 1 mg oE2 combined with 25 microg gestodene (oE2 + G, n = 33) for 13 cycles of 28 days, followed by 4 cycles of placebo in each group. Fasting serum concentrations of total, high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol, triglycerides, and Lp(a) were measured at baseline and in cycles 4, 13, and 17.
  
  
  RESULTS
  In cycle 13, a significant mean percentage decrease from baseline was found in all treatment groups compared with placebo in total cholesterol (tE2, -4.7%; oE2, -6.9%; oE2 + G, -10.5%) and LDL cholesterol (tE2, -5.8%; oE2, -12.6%; oE2 + G, -13.6%). For both oral groups, the reductions were already significant in cycle 4. None of the treatment groups showed a significant change in HDL cholesterol or triglycerides. In cycle 13, Lp(a) was decreased compared with placebo in the oE2 group (-6.6%) and the oE2 + G group (-8.2%). After washout, all observed changes had returned to baseline level, except for the decreases in total and LDL cholesterol in the oE2 + G group.
  
  
  CONCLUSIONS
  Oral E2 and E2 + G, and to a lesser extent transdermal E2, decreased total and LDL cholesterol. Lp(a) was lowered only by the oral treatments.
authors: Project Ageing Women and the Institute for Cardiovascular Research, the Department of Obstetrics & Gynecology, VU Medical Center, Amsterdam, The Netherlands.
authors: Majoie
authors: M
authors: Hemelaar
authors: Marius J
authors: MJ
authors: van der Mooren
authors: Velja
authors: V
authors: Mijatovic
authors: Anneke A
authors: AA
authors: Bouman
authors: Charles P T
authors: CP
authors: Schijf
authors: Maurice V A M
authors: MV
authors: Kroeks
authors: Henk R
authors: HR
authors: Franke
authors: Peter
authors: P
authors: Kenemans
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D004311:Double-Blind Method; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood / Q000187:drug effects*; D008875:Middle Aged; D009652:Norpregnenes / Q000008:administration & dosage*; D015990:Placebo Effect; D017698:Postmenopause / Q000097:blood*; D011372:Progestins / Q000008:administration & dosage*
chemical_list: D008055:Lipids; D017270:Lipoprotein(a); D009652:Norpregnenes; D011372:Progestins; C033273:Gestodene; D004958:Estradiol